BioSpace News Archive

Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.

Cerephex has been giving quality dental pharmaceuticals in CA since 2004. Quintessential aptitudes of our experts, selective desires of cleanliness and the latest in advancement amalgamate to spread smiles at Cerephex.

Aerpio Therapeutics merged with Aadi Bioscience in 2021.

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, pain, and various types of cancer.

At the heart of health care, you’ll find Kaiser Permanente. As the nation’s leading not-for-profit, integrated health plan, we make a difference in the lives of members, patients, and communities across the country.

Headquartered in Paris, France, it is the fifth largest pharmaceutical company in the world [3] and is dedicated to the research, development, production and marketing of pharmaceutical products in seven main areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.

Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services.